Avoiding late-stage colorectal cancer: The outpatient safety net.

2013 ◽  
Vol 31 (31_suppl) ◽  
pp. 177-177
Author(s):  
Joanne E. Schottinger ◽  
Michael H. Kanter ◽  
Andrea Smith

177 Background: The Institute of Medicine report "To Err is Human" highlighted two vulnerabilities that introduce possible diagnostic errors — information overload and failure to follow up abnormal cases. The Southern California Permanente Regional Safety Net program was instituted to identify, using electonic medical records, instances where these inadvertent outpatient safety lapses may have occurred and intervene before patient harm develops. A centralized regional team catches the omission and intervenes to ensure necessary follow up care, early diagnosis, treatment monitoring, or preventing harmful interactions from medications. Methods: For colorectal cancer detection and prevention, a safety net system was already in place to ensure the prompt evaluation of a positive fecal occult blood screening test with colonoscopy. However, evaluation of late stages of colorectal cancer at presentation revealed that failure to diagnose/follow up signs of iron deficiency anemia or rectal bleeding (often attributed to hemorrhoids) were opportunities to intervene. The electronic medical record is mined for evidence of iron deficiency anemia in laboratory results or a diagnosis of rectal bleeding that was not followed by a colonoscopy in patients aged 50-75. A list of these patients is reviewed quarterly by a gastroenterologist, who contacts the primary care physician to arrange colonoscopy. Results: During the first six months of the program, 42 patients, aged 52-75, underwent colonoscopy for evaluation of either evidence of iron deficiency anemia or rectal bleeding. Polypectomies were performed in 17 patients (40%) with pathology revealing adenomas in 13 patients and one patient with a bleeding carcinoid tumor. Other findings included hyperplastic polyps, hemorrhoids, diverticular disease, colitis, ulcer, and angiodysplastic lesions. Conclusions: Using an electronic medical record system, an outpatient safety net function allows proactive identification of possible safety issues in the population, helping to avoid late stage diagnoses and adverse outcomes. This system currently encompasses other cancer screening tests, medication monitoring, avoiding harmful medication interactions, and immunizations.

2020 ◽  
Vol 158 (6) ◽  
pp. S-1169
Author(s):  
Joshua Demb ◽  
Lin Liu ◽  
Caitlin C. Murphy ◽  
Chyke Doubeni ◽  
Maria Elena Martinez ◽  
...  

2007 ◽  
Vol 65 (5) ◽  
pp. AB270
Author(s):  
Stéphane Nahon ◽  
Pierre Lahmek ◽  
Francine Barclay ◽  
Gilles Macaigne ◽  
Cécile Poupardin ◽  
...  

2019 ◽  
Author(s):  
M Murzi-Pulgar ◽  
B Cuyàs Espí ◽  
S Bazaga Perez de Rozas ◽  
G Iborra Muñoz ◽  
D González-Juan ◽  
...  

2020 ◽  
Vol 7 ◽  
pp. 205435812093339
Author(s):  
Paweena Susantitaphong ◽  
Monchai Siribumrungwong ◽  
Kullaya Takkavatakarn ◽  
Kamonrat Chongthanakorn ◽  
Songkiat Lieusuwan ◽  
...  

Background: There is no consensus on intravenous (IV) iron supplement dose, schedule, and serum ferritin target in functional iron deficiency anemia to maintain optimum target levels of iron stores by several guidelines. Objective: To examine the effect of IV iron supplementation to different targets of serum ferritin on erythropoietin dose and inflammatory markers in chronic hemodialysis (HD) patients with functional iron deficiency anemia. Design: A multicenter, randomized, open-label study. Setting: In a developing country, Thailand. Patients: Chronic HD patients with functional iron deficiency anemia. Measurements: Erythropoietin resistance index, high-sensitivity C-reactive protein, and fibroblast growth factor 23. Methods: Two hundred adult chronic HD patients with transferrin saturation less than 30% and serum ferritin of 200 to 400 ng/mL were randomized 1:1 to maintain serum ferritin 200 to 400 ng/mL (low-serum ferritin group, N = 100) or 600 to 700 ng/mL (high-serum ferritin group, N = 100). During a 6-week titration period, participants randomized to the high-serum ferritin group initially received 600 mg IV iron (100 mg every week), while the participants in the low-serum ferritin group did not receive IV iron. During the 6-month follow-up period, the dose of IV iron was adjusted by protocol. Results: The mean dose of IV iron was 108.3 ± 28.2 mg/month in the low-serum ferritin group and 192.3 ± 36.2 mg/month in the high-serum ferritin group. The mean serum ferritin was 367.0 ± 224.9 ng/mL in the low ferritin group and 619.6 ± 265.2 ng/mL in the high ferritin group. The erythropoietin resistance index was significantly decreased in the high-serum ferritin group compared to the low-serum ferritin group after receiving IV iron in the 6-week titration period (mean difference: −113.43 ± 189.14 vs 41.08 ± 207.38 unit/week/g/dL; P < .001) and 3-month follow-up period (mean differences: −88.88 ± 234.43 vs −10.48 ± 217.75 unit/week/g/dL; P = .02). Limitations: Short follow-up period. Conclusion: Maintaining a serum ferritin level of 600 to 700 ng/mL by IV iron administration of approximately 200 mg per month as a maintenance protocol can decrease erythropoietin dose requirements in chronic HD patients with functional iron deficiency anemia. Trials registration: The study was registered with the Thai Clinical Trials Registry TCTR20180903003.


Hematology ◽  
1996 ◽  
Vol 1 (1) ◽  
pp. 65-73 ◽  
Author(s):  
Susan K. Parsons ◽  
Mark D. Fleming ◽  
David G. Nathan ◽  
Nancy C. Andrews

Transfusion ◽  
2017 ◽  
Vol 57 (12) ◽  
pp. 3040-3048 ◽  
Author(s):  
MaríaJesús Laso-Morales ◽  
Carlos Jericó ◽  
Susana Gómez-Ramírez ◽  
Jordi Castellví ◽  
Lorenzo Viso ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document